key: cord-0749820-u536t747
authors: Yakoot, Mostafa
title: Nonsignificant trends in COVID‐19 trials: Is there a significance?
date: 2022-01-11
journal: J Med Virol
DOI: 10.1002/jmv.27565
sha: ba944fca1656744c923a288dc205f5b87a36f4f6
doc_id: 749820
cord_uid: u536t747

Hundreds of clinical trials have been conducted on already available antiviral drugs or natural/herbal substances to repurpose for the treatment of COVID‐19, but with no conclusively consistent statistically significant positive results. Remdesvir, for example, is facing a confusing situation, after the two major large multinational studies SOLIDARITY and DisCoVeRy concluded that there are no significant survival benefits. In this viewpoint article, we claimed that the inconsistent time to initiate antiviral drugs during the course of COVID‐12 studies is the major contributing factor for this dilemma. We explained that patients already on mechanical ventilation at the study baseline are considered from a biologically different population than other severity groups. We provided a simple meta‐meta‐analysis to show how excluding them from statistical analysis could affect the statistical significance and conclusions.

In my viewpoint, I can argue that the inconsistent time to initiate antiviral drug therapy during the course of the disease is the major contributing factor for this dilemma.

Back to review basic science; it is already well-defined that the natural history of symptomatic COVID-19 starts by early rapid viral replication that reaches peak levels during the first week of symptoms. Then the virus levels steadily decline, independent of whether patients will recover spontaneously or progress to a severe or critical stage of infection. 1 all the five studies that included patients in the early phase (or with mild disease) together with other levels of severity (or balanced subsets of severity) showed trends for lower all-cause mortality at Day 28 by remdesivir. [4] [5] [6] [7] [8] Whereas the other two studies that excluded this subset (early/mild cases) did not show these trends but even a reversed trend affecting the overall result of the metaanalysis. 9, 10 Away from complicated statistical procedures, we simply excluded these two unbalanced studies from meta-analysis in-order to reduce heterogeneity and for their high risk of bias. We conducted a simple meta-analysis for the risk of all-cause mortality at Day 28 including all patients of the other five studies after excluding all data of the subset of patients who were under mechanical ventilation at baseline in the WHO SOLIDARITY trial from analysis as shown in Table 2 . 

The authors declare that there are no conflict of interests.

The data that support the findings of this study are available in COVID-NMA at https://covid-nma.com/metacovid/. These data were derived from the following resources available in the public 

COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal

The importance of understanding the stages of COVID-19 in treatment and trials

metaCOVID: an R-Shiny application for living meta-analyses of COVID-19 trials

Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Repurposed antiviral drugs for COVID-19-interim WHO Solidarity Trial results

Remdesivir for the treatment of COVID-19-final report (The Adaptive Covid-19 Treatment Trial (ACTT-1)

Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial

Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Non-significant Trends in COVID-19 Trials: Is There a Significance